TNSN04191A1 - Composes qui modulent l'activite de ppar et procedes pour leur preparation - Google Patents
Composes qui modulent l'activite de ppar et procedes pour leur preparationInfo
- Publication number
- TNSN04191A1 TNSN04191A1 TNP2004000191A TNSN04191A TNSN04191A1 TN SN04191 A1 TNSN04191 A1 TN SN04191A1 TN P2004000191 A TNP2004000191 A TN P2004000191A TN SN04191 A TNSN04191 A TN SN04191A TN SN04191 A1 TNSN04191 A1 TN SN04191A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds
- methods
- preparation
- shows
- ppar activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
LA PRESENTE INVENTION FAIT CONNAITRE DES COMPOSES QUI MODIFIENT L'ACTIVITE DE PPAR. LA PRESENTE INVENTION FAIT CONNAITRE EGALEMENT DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DES COMPOSES; DES COMPOSITIONS PHARMACEUTIQUEMENT ACCEPTABLES COMPRENANT LES COMPOSES OU LEURS SELS; ET DES METHODES POUR LEUR UTILISATION COMME AGENTS THERAPEUTIQUES POUR LE TRAITEMENT OU LA PREVENTION DE L'HYPERLIPIDEMIE; DE L'HYPERCHOLESTEROLEMIE; DE L'OBESITE; DE TROUBLES DE L'ALIMENTATION; DE L'HYPERGLYCEMIE; DE L'ATHEROSCLEROSE; DE L'HYPERTRIGLYCERIDEMIE; DE L'HYPERINSULINEMIE ET DU DIABETE CHEZ UN MAMMIFERE; AINSI QUE DES METHODES DE SUPPRESSION DE L'APPETIT ET DE MODULATION DES TAUX DE LEPTINE CHEZ UN MAMMIFERE. LA PRESENTE INVENTION FAIT CONNAITRE EGALEMENT DES PROCEDES POUR LA PREPARATION DES COMPOSES DECRITS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37050802P | 2002-04-05 | 2002-04-05 | |
US38602602P | 2002-06-05 | 2002-06-05 | |
PCT/IB2003/001121 WO2003084916A2 (fr) | 2002-04-05 | 2003-03-24 | Composes modulant l'activite ppar et leurs procedes de preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN04191A1 true TNSN04191A1 (fr) | 2007-03-12 |
Family
ID=28794388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2004000191A TNSN04191A1 (fr) | 2002-04-05 | 2004-10-04 | Composes qui modulent l'activite de ppar et procedes pour leur preparation |
Country Status (35)
Country | Link |
---|---|
US (4) | US6875780B2 (fr) |
EP (1) | EP1494989A2 (fr) |
JP (2) | JP3816922B2 (fr) |
KR (1) | KR100687166B1 (fr) |
CN (1) | CN1649820A (fr) |
AP (1) | AP1772A (fr) |
AR (1) | AR039239A1 (fr) |
AU (1) | AU2003212578A1 (fr) |
BR (1) | BR0309169A (fr) |
CA (1) | CA2481246C (fr) |
CO (1) | CO5640080A2 (fr) |
DO (1) | DOP2003000620A (fr) |
EA (2) | EA009518B1 (fr) |
GE (1) | GEP20074244B (fr) |
GT (3) | GT200300075A (fr) |
HN (1) | HN2003000113A (fr) |
HR (1) | HRP20040916A2 (fr) |
IL (1) | IL164015A0 (fr) |
IS (1) | IS7429A (fr) |
MA (1) | MA27189A1 (fr) |
MX (1) | MXPA04009727A (fr) |
MY (1) | MY134199A (fr) |
NI (1) | NI200300042A (fr) |
NO (1) | NO20044795L (fr) |
NZ (1) | NZ554477A (fr) |
OA (1) | OA12859A (fr) |
PA (1) | PA8570701A1 (fr) |
PE (1) | PE20040307A1 (fr) |
PL (1) | PL373651A1 (fr) |
RS (1) | RS82904A (fr) |
TN (1) | TNSN04191A1 (fr) |
TW (1) | TWI249522B (fr) |
UA (1) | UA76838C2 (fr) |
UY (1) | UY27749A1 (fr) |
WO (1) | WO2003084916A2 (fr) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517884B2 (en) * | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
GB0029974D0 (en) * | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
EP1559350A4 (fr) * | 2002-06-24 | 2007-10-24 | Sugatsune Kogyo | Dispositif de rangement de parapluies et dispositif de retenue de parapluies |
US20060241157A1 (en) * | 2003-01-06 | 2006-10-26 | Conner Scott E | Heterocyclic ppar modulators |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
EP1630152A4 (fr) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | Compose cyclique condense |
JP4928941B2 (ja) | 2003-09-19 | 2012-05-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 |
WO2005040104A1 (fr) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd. | Nouveaux composes et leurs applications medicales, leur procede de preparation, et compositions pharmaceutiques les contenant |
JP2007527416A (ja) * | 2003-10-31 | 2007-09-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ペルオキシソーム増殖因子活性化受容体(ppar)二重作動薬として有用なフェノキシ酢酸誘導体 |
AU2004291260A1 (en) | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Benzannelated compounds as PPAR activators |
JP2007509996A (ja) * | 2003-11-05 | 2007-04-19 | エフ.ホフマン−ラ ロシュ アーゲー | Ppar活性化剤としてのヘテロアリール誘導体 |
WO2005049573A1 (fr) * | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Derives de phenyle utilises comme agonistes de ppar |
WO2005054213A1 (fr) * | 2003-12-02 | 2005-06-16 | Shionogi & Co., Ltd. | Derive d'isoxazole presentant un effet agoniste sur le recepteur active par les proliferateurs des peroxysomes |
US7507832B2 (en) | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
JP2007520471A (ja) * | 2003-12-22 | 2007-07-26 | イーライ リリー アンド カンパニー | Ppar受容体調節物質としての二環式誘導体 |
TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
EP1737809B1 (fr) * | 2004-02-27 | 2013-09-18 | Amgen, Inc | Composes, compositions pharmaceutiques et procedes d'utilisation dans le traitement de troubles metaboliques |
WO2005085235A1 (fr) * | 2004-03-09 | 2005-09-15 | F. Hoffmann-La Roche Ag | Derives de pyrazolyl-indolyle utilises comme activateurs de ppar |
US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
WO2005105736A1 (fr) * | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
JP2007536341A (ja) * | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | Pparアゴニストとしてのフェノキシ酢酸誘導体 |
ES2352085T3 (es) * | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
MXPA06013196A (es) * | 2004-05-14 | 2007-02-14 | Irm Llc | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar). |
US7745445B2 (en) | 2004-05-14 | 2010-06-29 | Irm Llc | Compounds and compositions as PPAR modulators |
WO2005115383A2 (fr) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Triazoles substitués comme modulateurs de ppar et méthodes de préparation |
US20060014785A1 (en) * | 2004-05-25 | 2006-01-19 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
US20070232647A1 (en) * | 2004-05-25 | 2007-10-04 | Goetze Leopold F | Use of Ppar Agonists to Treat Ruminants |
CN1997619B (zh) | 2004-07-01 | 2010-08-25 | 霍夫曼-拉罗奇有限公司 | 包含乙炔基的苯基衍生物 |
US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
MY145712A (en) * | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
US20070190079A1 (en) * | 2004-10-29 | 2007-08-16 | Kalypsys, Inc. | Methods for the selective modulation of ppar |
EP1805158B1 (fr) * | 2004-10-29 | 2018-06-27 | Kalypsys, Inc. | Composes bicycliques à substitution sulfonyle, modulateurs des ppar |
EP1819681B1 (fr) * | 2004-11-23 | 2009-08-12 | Warner-Lambert Company LLC | Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
BRPI0612730A2 (pt) | 2005-06-30 | 2010-11-30 | Novo Nordisk As | compostos, suas preparações e uso |
WO2007030567A2 (fr) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Composes actifs sur les ppar |
WO2007033002A1 (fr) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Acides propanoïques 3-substitués par un groupement 4-hydroxyphényle à conformation contrainte pouvant être employés dans le traitement de troubles métaboliques |
JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
WO2007051095A1 (fr) * | 2005-10-25 | 2007-05-03 | Kalypsys, Inc. | Sels de modulateurs de ppar et procedes de traitement de troubles metaboliques |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
CN101007798B (zh) * | 2006-01-24 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途 |
WO2007101864A2 (fr) * | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Nouveaux composés, leur préparation et utilisation |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
JP2009530281A (ja) * | 2006-03-14 | 2009-08-27 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
PE20080188A1 (es) * | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
US20070249519A1 (en) * | 2006-04-20 | 2007-10-25 | Kalypsys, Inc. | Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease |
TW200745059A (en) * | 2006-05-16 | 2007-12-16 | Kalypsys Inc | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
WO2008030520A1 (fr) * | 2006-09-07 | 2008-03-13 | Amgen Inc. | Modulateurs hétérocycliques du récepteur couplé à la protéine g (gpr40) |
US7687526B2 (en) * | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
CN102584685A (zh) | 2006-12-02 | 2012-07-18 | 财团法人首尔大学校产学协力财团 | 作为ppar配体的芳基化合物及其用途 |
US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
CN101616900A (zh) * | 2007-02-23 | 2009-12-30 | 伊莱利利公司 | 过氧化物增殖物激活受体调节剂 |
ATE525375T1 (de) * | 2007-03-13 | 2011-10-15 | Merck Sharp & Dohme | Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 |
US7572934B2 (en) * | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
EP2184277B1 (fr) * | 2007-07-25 | 2015-07-01 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Dérivés d'arylpyrimidine, procédés de préparation et utilisations pharmaceutiques de ces dérivés |
WO2009048527A1 (fr) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Modulateurs du gpr40 à biphényle substitué |
AU2008338963A1 (en) * | 2007-12-13 | 2009-06-25 | Sri International | PPAR-delta ligands and methods of their use |
JP2011515341A (ja) * | 2008-03-06 | 2011-05-19 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体 |
US8461183B2 (en) | 2008-05-26 | 2013-06-11 | Genfit | PPAR agonist compounds, preparation and uses |
WO2010018547A1 (fr) * | 2008-08-13 | 2010-02-18 | Pfizer Inc. | Composés aminoquinoline |
AU2009303475B2 (en) * | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
WO2012178142A1 (fr) * | 2011-06-23 | 2012-12-27 | Metabolic Solutions Development Company, Llc | Composés épargnant les ppar et combinaisons pour le traitement du diabète et d'autres maladies métaboliques |
EP2870219B1 (fr) * | 2012-07-06 | 2016-05-25 | Merck Patent GmbH | Composés bimésogènes et milieux mésogènes |
MX2015014666A (es) | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
CA2923422C (fr) | 2013-09-09 | 2021-09-07 | Vtv Therapeutics Llc | Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie |
WO2016055901A1 (fr) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Composés d'amide substitué |
CN106831437B (zh) * | 2016-02-03 | 2019-06-21 | 华中师范大学 | 含硝基乙烯基的酯类化合物及其制备方法和应用 |
CA3069720A1 (fr) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides utilises en tant qu'inhibiteurs des canaux sodiques |
KR20200094734A (ko) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 헤테로사이클릭 화합물 |
MX2020003341A (es) | 2017-10-18 | 2020-09-17 | Jubilant Epipad LLC | Compuestos de imidazo-piridina como inhibidores de pad. |
JP7279057B6 (ja) | 2017-11-06 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pd1/pd-l1活性化の阻害剤としてのピリミジン誘導体 |
EP3704120B1 (fr) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Composés hétérocycliques utilisés en tant qu'inhibiteurs de prmt5 |
MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
EP3911648A4 (fr) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
CN114026060A (zh) * | 2019-06-28 | 2022-02-08 | 住友化学株式会社 | 丙烯酸酯衍生物、其用途及其制造中间体 |
CN112824394A (zh) * | 2019-11-21 | 2021-05-21 | 中国科学院上海药物研究所 | PPARs-FXR多靶点小分子激动剂及其制备方法和用途 |
KR20230054373A (ko) | 2020-07-22 | 2023-04-24 | 르네오 파마슈티컬스, 인크. | 결정질 ppar-델타 작용제 |
WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3526235A1 (de) | 1984-11-16 | 1986-05-22 | Bayer Ag, 5090 Leverkusen | Fluessigkristallzusammensetzungen |
DE4002374C2 (de) | 1990-01-27 | 1999-04-15 | Merck Patent Gmbh | Partiell fluorierte Verbindungen und deren Verwendung als Komponente flüssig kristalliner Medien |
DE4222565A1 (de) | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
JP3187611B2 (ja) | 1993-05-17 | 2001-07-11 | キヤノン株式会社 | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置 |
WO1996004228A1 (fr) | 1994-08-04 | 1996-02-15 | Sumitomo Chemical Company, Limited | Composes dihalopropene, agents insecticides/acaricides les contenant et intermediaires pour leur fabrication |
JPH09194418A (ja) | 1996-01-18 | 1997-07-29 | Sumitomo Chem Co Ltd | ジハロプロペン化合物、その用途およびその製造中間体 |
WO1997028149A1 (fr) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Procede pour augmenter les niveaux de cholesterol hdl |
DE69720429T9 (de) | 1996-02-02 | 2004-09-23 | Merck & Co., Inc. | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
WO1998007699A1 (fr) | 1996-08-19 | 1998-02-26 | Japan Tobacco Inc. | Derives d'acide propionique et applications de ces derives |
ATE451346T1 (de) | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
PT1206457E (pt) | 1999-08-27 | 2004-03-31 | Lilly Co Eli | Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars |
AU7962200A (en) * | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
IL159002A0 (en) | 2001-06-07 | 2004-05-12 | Lilly Co Eli | Modulators of peroxisome proliferator activated receptors (ppar) |
IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
US6833380B2 (en) * | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6867224B2 (en) * | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
-
2003
- 2003-01-22 US US10/347,749 patent/US6875780B2/en not_active Expired - Fee Related
- 2003-03-06 NI NI200300042A patent/NI200300042A/es unknown
- 2003-03-24 BR BR0309169-4A patent/BR0309169A/pt not_active IP Right Cessation
- 2003-03-24 KR KR1020047015763A patent/KR100687166B1/ko not_active IP Right Cessation
- 2003-03-24 AU AU2003212578A patent/AU2003212578A1/en not_active Abandoned
- 2003-03-24 CN CNA038097915A patent/CN1649820A/zh active Pending
- 2003-03-24 CA CA002481246A patent/CA2481246C/fr not_active Expired - Fee Related
- 2003-03-24 RS YUP-829/04A patent/RS82904A/sr unknown
- 2003-03-24 IL IL16401503A patent/IL164015A0/xx unknown
- 2003-03-24 MX MXPA04009727A patent/MXPA04009727A/es active IP Right Grant
- 2003-03-24 AP APAP/P/2004/003135A patent/AP1772A/en active
- 2003-03-24 EA EA200401153A patent/EA009518B1/ru not_active IP Right Cessation
- 2003-03-24 WO PCT/IB2003/001121 patent/WO2003084916A2/fr active Application Filing
- 2003-03-24 UA UA20041008021A patent/UA76838C2/uk unknown
- 2003-03-24 JP JP2003582115A patent/JP3816922B2/ja not_active Expired - Fee Related
- 2003-03-24 DO DO2003000620A patent/DOP2003000620A/es unknown
- 2003-03-24 GE GEAP8431A patent/GEP20074244B/en unknown
- 2003-03-24 PL PL03373651A patent/PL373651A1/xx unknown
- 2003-03-24 NZ NZ554477A patent/NZ554477A/en unknown
- 2003-03-24 EP EP03708403A patent/EP1494989A2/fr not_active Withdrawn
- 2003-03-24 EA EA200700969A patent/EA200700969A1/ru unknown
- 2003-03-24 OA OA1200400261A patent/OA12859A/en unknown
- 2003-04-01 GT GT200300075A patent/GT200300075A/es unknown
- 2003-04-01 GT GT200300075BL patent/GT200300075BA/es unknown
- 2003-04-01 PE PE2003000327A patent/PE20040307A1/es not_active Application Discontinuation
- 2003-04-01 GT GT200300075AK patent/GT200300075AA/es unknown
- 2003-04-02 MY MYPI20031235A patent/MY134199A/en unknown
- 2003-04-03 AR ARP030101164A patent/AR039239A1/es unknown
- 2003-04-03 UY UY27749A patent/UY27749A1/es not_active Application Discontinuation
- 2003-04-04 TW TW092107732A patent/TWI249522B/zh not_active IP Right Cessation
- 2003-04-04 HN HN2003000113A patent/HN2003000113A/es unknown
- 2003-04-04 PA PA20038570701A patent/PA8570701A1/es unknown
-
2004
- 2004-08-30 IS IS7429A patent/IS7429A/is unknown
- 2004-09-17 CO CO04092873A patent/CO5640080A2/es not_active Application Discontinuation
- 2004-09-28 MA MA27877A patent/MA27189A1/fr unknown
- 2004-10-04 TN TNP2004000191A patent/TNSN04191A1/fr unknown
- 2004-10-05 HR HRP20040916 patent/HRP20040916A2/hr not_active Application Discontinuation
- 2004-11-02 US US10/979,617 patent/US6939875B2/en not_active Ceased
- 2004-11-02 US US10/979,629 patent/US6964983B2/en not_active Expired - Fee Related
- 2004-11-04 NO NO20044795A patent/NO20044795L/no not_active Application Discontinuation
-
2005
- 2005-11-28 US US11/288,022 patent/USRE39916E1/en not_active Expired - Fee Related
- 2005-12-14 JP JP2005360431A patent/JP2006151985A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN04191A1 (fr) | Composes qui modulent l'activite de ppar et procedes pour leur preparation | |
TNSN04168A1 (fr) | Derives de thiazole et d'oxazole qui modulent l'activite de ppar | |
TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN04167A1 (fr) | Derives de thiazole et d'oxazole qui modulent l'activite de ppar | |
TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
CA2206837A1 (fr) | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose | |
TNSN98024A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN99110A1 (fr) | Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant | |
CA2238465A1 (fr) | Composes triaromatiques, compositions les contenant et utilisations | |
DZ2752A1 (fr) | Composés et compositions pharmaceutiques pour le traitement du paludisme. | |
TNSN99135A1 (fr) | Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression | |
TNSN99133A1 (fr) | Procede perfectionne pour la preparation de bases de schiff et produits ainsi obtenus | |
MA26732A1 (fr) | Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation | |
IL134263A0 (en) | Use of phanquinone for the treatment of alzheimer's disease | |
GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
CA2291650A1 (fr) | Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant | |
DE60025215D1 (de) | L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit | |
DZ2564A1 (fr) | Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés. | |
TNSN98206A1 (fr) | Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose | |
EP0687687A3 (fr) | Compositions pharmaceutiques pour la prévention et le traitement de désordres de la coagulation du sang | |
IL124730A0 (en) | Compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of gastrointestinal disorders | |
MY113635A (en) | Methods and compositions for the prevention and treatment of gastrointestinal disorders | |
IL124729A0 (en) | Compositions containing bismuth for the prevention and treatment of gastrointestinal disorders | |
IL124742A0 (en) | Compositions comprising a bismuth compound for the prevention and treatment of gastrointestinal disorders | |
TNSN99199A1 (fr) | FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc A LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION |